Pharvaris, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatterjee from JonesTrading maintained a Buy rating on the stock and has a $43.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Debanjana Chatterjee’s rating is based on the promising results from Pharvaris’s Phase 3 RAPIDe-3 trial for IR deucrictibant, which demonstrated a rapid onset of symptom relief for HAE attacks. The trial’s primary endpoint showed a median time to symptom relief of 1.3 hours, aligning with expectations and outperforming a competitor’s results.
Additionally, all secondary efficacy endpoints were met, with significant improvements in time to substantial symptom relief and complete symptom resolution compared to placebo. The competitive profile of IR deucrictibant suggests it is well-positioned to gain market share in the HAE on-demand market, potentially coexisting with existing treatments while offering a less invasive alternative to current therapies.
Chatterjee covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Opus Genetics, and EyePoint Pharmaceuticals. According to TipRanks, Chatterjee has an average return of 30.8% and a 63.54% success rate on recommended stocks.
In another report released on November 24, Morgan Stanley also maintained a Buy rating on the stock with a $37.00 price target.